Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADP064-ABC
- Development stage
- Preclinical
- Lead developer
- Alector
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
ADP064-ABC is an investigational therapeutic candidate developed by Alector for the treatment of neurodegenerative diseases, specifically Alzheimer's disease and frontotemporal dementia. It targets tau pathology by combining an anti-tau small interfering RNA (siRNA) with Alector’s proprietary Brain Carrier (ABC) technology. The siRNA component is designed to inhibit the synthesis of tau mRNA and protein, thereby reducing pathological tau accumulation in the brain. The ABC platform aims to enhance delivery across the blood-brain barrier. This dual approach seeks to slow cognitive decline associated with tauopathies by preventing toxic tau buildup[1][2][3][4][5][7].
- Other names
- Alector Brain Carrier-enabled tau siRNA
02
Targets
MAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on ADP064-ABC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADP064-ABC.